secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001558370-22-010227
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics shareholders reject advisory say-on-pay and annual frequency vote
--------------------------------------------------------------------------------

- Proposal 4 (advisory vote on executive compensation) defeated: 25.8M for, 61.2M against.
- Proposal 5 (advisory vote on frequency): 66.9M voted for annual, but board will retain triennial frequency.
- Director Yann Echelard and Daniel Hume each received only ~31.5% support, Sagar Lonial got 26.4%.
- Shareholders approved 2022 Incentive Plan (53.9M for, 33.3M against) and ratified KPMG (114.0M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/0001558370-22-010227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/tgtx-20220616x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer